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β-lactams are antibiotic molecules able to inhibit cell wall biosynthesis. Among other 
mechanisms, resistance in Gram-negative bacteria is mostly associated with production 
of β-lactamase enzymes able to bind and hydrolyze the β-lactam ring. Extended-spectrum 
β-lactamases extend this ability also to third- and fourth-generation cephalosporins, as 
well as to carbapenems and monobactams. Vibrio cholerae is the causative agent of 
epidemic cholera and a public health burden for developing countries like Bangladesh. 
Although appropriate oral or intravenous rehydration is the therapy of choice for cholera, 
severe infections and V. cholerae-associated septicemia are treated with antimicrobial 
drugs, including doxycycline, erythromycin, azithromycin, ciprofloxacin, and/or third-gen-
eration cephalosporins. In the years after the introduction of antibiotics in clinical practice, 
V. cholerae developed resistance to commonly used drugs worldwide mostly through 
gene acquisition via horizontal gene transfer. Reduced susceptibility of V. cholerae to 
third-generation cephalosporins has been occasionally documented. However, carbap-
enemase-producing V. cholerae has been reported at higher rates than resistance to 
extended-spectrum β-lactams, mainly associated with blaNDM-1 emergence and success-
ful plasmid dissemination. Recent findings suggest limited β-lactam resistance is present 
in V. cholerae O1 isolates collected during ecological and epidemiological surveillance in 
Bangladesh. However, a trend to intermediate-susceptibility insurgence was observed. 
Horizontal gene transfer of β-lactam resistance from enteric pathogens to environmental 
microorganisms should not be underrated, given the ability of V. cholerae to acquire new 
genetic information.
Keywords: Vibrio cholerae, cholera, Bangladesh, extended-spectrum β-lactams, carbapenems, antibiotic 
resistance, aquatic environment, clinical environment
iNtrODUctiON
β-lactams are assorted antibiotic molecules able to inhibit cell wall biosynthesis. Resistance to these 
drugs can be the result of altered permeability, antibiotic target site alteration, or antibiotic degrada-
tion (1). The latter represents the primary resistance mechanism in Gram-negative bacteria producing 
β-lactamase enzymes able to bind and hydrolyze the β-lactam ring (2). β-lactamases have extensively 
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diversified in response to the clinical use of new generations of 
β-lactams, including the clinically significant extended-spectrum 
β-lactamases (ESBLs) CTX-M-, TEM-, and SHV-type enzymes 
(3). Carbapenemases are ESBLs that recognize almost all hydro-
lyzable β-lactams, including carbapenems (imipenem, ertapenem, 
meropenem, and doripenem), the last-line therapeutics to treat 
multidrug-resistant Gram-negative infections (4). Carbapenem 
resistance in Enterobacteriaceae constitutes an important and 
growing public health threat, especially since the appearance of 
the powerful enzyme NDM-1 (5), whose presence during the past 
years was reported worldwide (6).
The majority of diarrheal diseases in Bangladesh are endemic 
and waterborne since surface water can be heavily contaminated 
due to poor sanitation and hygiene (7) and access to safe drink-
ing water is problematic (8). Together with enterotoxigenic 
Escherichia coli, Vibrio cholerae is one of the leading causes of 
enteric infections in the country. V. cholerae is a natural inhabit-
ant of estuarine brackish waters and it can thrive in the human 
gut, causing mild to severe infections and cholera. Today, more 
than 200 serotypes of V. cholerae have been documented, with 
O1 and O139 being the only serotypes associated with epidemic 
cholera (9). Cholera can occur both as endemic disease with 
seasonal peaks and in epidemics associated with floods, droughts, 
and cyclones that occur in the country (10). Infections other 
than cholera are caused by non-epidemic V. cholerae serogroups, 
collectively referred to as V. cholerae non-O1/non-O139, with 
infections reported worldwide (11, 12).
According to World Health Organization guidelines, oral 
rehydration is the therapy of choice for V. cholerae infections, 
independent of serotype (13). It is recommended that severe 
infections and septicemia be treated with antimicrobial therapy, 
choosing an effective antibiotic according to local antibiotic sus-
ceptibility patterns. Doxycycline is recommended as the first-line 
treatment for V. cholerae O1 or O139 infections in adults, while 
erythromycin or azithromycin are recommended for children 
and pregnant women. Ciprofloxacin and/or third-generation 
cephalosporins (ceftazidime and ceftriaxone) are recommended 
for V. cholerae non-O1/non-O139 infections (14).
After the introduction of antibiotics into clinical practice, 
V. cholerae remained relatively susceptible till the end of the 1970s 
(15). Within a few years however, this scenario changed dramati-
cally, with V. cholerae strains found to be resistant to commonly 
used drugs worldwide (16–18), a phenomenon likely attributable 
to indiscriminate use of antibiotics. Today, V.   cholerae can be 
resistant virtually to all commonly used antibiotics, including 
ampicillin, quinolones, ciprofloxacin, tetracycline, cotrimoxa-
zole, and macrolides (19). The reasons are multiple and rely on 
chromosomal mutations, enhanced efflux pumps, and acquisi-
tion of drug altering enzymes via horizontal gene transfer (20). 
The latter has proven to be the most powerful, as a result of a 
variety of mobile elements circulating amongst V. cholerae, such 
as conjugative plasmids (21, 22), integrative conjugative elements 
(23), and mobile genomic islands (24).
The full extent of antibiotic resistance in V. cholerae is not yet 
known because of limited data. Non-cholera Vibrio infections are 
not mandatorily notifiable in several countries and annual figures 
on cholera cases may be significantly under estimated, especially 
when labeled as “acute watery diarrhea,” in south-eastern and 
central Asia (10). The first clinical multi-resistant V. cholerae O1 
in Bangladesh was isolated in 1979, displaying plasmid-mediated 
resistance to tetracycline, ampicillin, kanamycin, streptomycin, 
and trimethoprim–sulfamethoxazole (25). Several studies since 
and the current dissemination of carbapenemases and ESBLs 
make it mandatory to understand this phenomenon, especially 
because of the higher mortality, morbidity, and increased health 
treatment costs associated with resistance to β-lactams (26).
tHirD-GeNerAtiON cePHALOsPOriN 
AND cArBAPeNeM resistANce  
iN V. cholerae
The first reports of V. cholerae O1 showing strong reduced 
susceptibility to cefotaxime, ceftazidime, and/or aztreonam 
appeared during the first Argentinean cholera outbreak, which 
was caused by an ESBL-producing isolate in the 1990s (27). This 
phenotype was associated with two plasmid-mediated ESBLs 
of the CTX-M- and PER-2-type (28). After a long hiatus, new 
cases of reduced susceptibility to third-generation cephalo-
sporins were described in V. cholerae O1, mostly in the Indian 
Subcontinent. Resistance to ceftriaxone was originally reported 
in pediatric cases from Puducherry, India in 2008–2010 (29, 30) 
and similar findings were described in Karnataka, South India, 
where cephalosporin-resistant strains were found to produce 
ESBLs (31). Due to lack of genetic analysis, the exact nature of 
the resistance mechanisms of the reduced susceptibilities is not 
clear. The most recent genetic characterization of multidrug-
resistant, ESBL-producing V.  cholerae was a plasmid-borne 
blaTEM-63 in V. cholerae O1 associated with a cholera outbreak 
in South Africa in 2008 (32), and an ISCR1-mediated blaPER-1 
embedded in a class 1 integron on a conjugative IncA/C plasmid 
in a clinical V. cholerae non-O1/non-O139 isolate from human 
blood in China (33).
Clearly, extended-spectrum β-lactamases are uncommon in 
V. cholerae, as well as in other Vibrionaceae, with only two find-
ings to date. Vibrio fluvialis isolated from cholera-like diarrheal 
patients in West Bengal, India in 2009 encoded a 150-kb plasmid 
harboring blaSHV and blaCTX-M-3, together with the quinolone 
resistance gene qnrA1, and ciprofloxacin-resistance gene aac(6)-
Ib-cr (34). Vibrio parahaemolyticus of food origin from China 
was reported to carry either the AmpC β-lactamase blaCMY-2 on 
a 150-kb IncA/C-type conjugative plasmid, previously described 
in Enterobacteriaceae (35), or a 200-kb conjugative plasmid 
encoding blaPER-1, conferring resistance to both third- and fourth-
generation cephalosporins (36, 37).
Carbapenemase-producing V. cholerae has been reported 
at a higher rate than ESBLs. The first description in Western 
countries was in southern France, where V. cholerae non-O1/
non-O139 was isolated from a yellow-legged gull and found to 
encode both blaVIM-1 and blaVIM-4 on an IncA/C plasmid (38). 
Shortly after, the novel transferable carbapenemase blaVCC-1 was 
identified in a non-toxigenic strain of V. cholerae non-O1/non-
O139 during antimicrobial resistance surveillance of food in 
Canada (39). VCC-1, the first class A carbapenemase to be found 
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in a member of the Vibrionaceae, can hydrolyze penicillin, first-
generation cephalosporins, aztreonam, and carbapenems but 
not second- and third-generation cephalosporins. Most notably, 
blaNDM-1 has been detected in environmental V. cholerae non-O1/
non-O139 in southern Vietnam (40), in clinical V. cholerae O1 in 
India together with the AmpC β-lactamase blaDHA gene (41), in 
a polymicrobial infection (V. cholerae, Acinetobacter baumannii, 
Staphylococcus aureus, and Pseudomonas aeruginosa) in the UK 
(42), and from water seepage in New Delhi, India (43). The suc-
cessful spread of blaNDM-1 can be attributed to its association with 
conjugative plasmids (44) and emphasizes the extent to which 
blaNDM-1 can disseminate among different species outside of the 
Enterobacteriaceae.
esBL- AND cArBAPeNeMAse-
MeDiAteD resistANce iN BANGLADesH
Antibiotic resistance is a serious threat in Bangladesh and has 
been for decades, most likely a result of unrestricted use of antimi-
crobial drugs to treat enteric infections, particularly those caused 
by V. cholerae, Salmonella, Shigella, and enterotoxigenic E.  coli 
(45). In the recent years, ESBL- and carbapenemase-mediated 
resistance has been found to be ubiquitous and has been detected 
in a variety of bacterial hosts.
blaCTX-M-15 is the dominant ESBL variant circulating in 
Bangladesh. It has been reported mainly in E. coli found in 
wild birds and aquatic systems (46), in household pigeons (47), 
poultry (48), urban surface water (49), and in epidemic E. coli 
isolates from both patients and crows scavenging poorly managed 
hospital waste dumps (50). On occasion, other ESBL genes have 
been found to be associated with blaCTX-M-15, such as blaCTX-M-14 in 
wild birds (51), or blaCTX-M-27, blaSHV-2, and/or blaSHV-12 in E. coli 
and Enterobacter cloacae from environmental urban water (52). 
The clinical scenario is not very different, with blaCTX-M-15 prevail-
ing (53), although bacterial species other than E. coli with the 
ESBL phenotype have been described (54–58). The first clinical 
Salmonella typhi positive for both blaTEM and blaCTX-M was recently 
reported to have been isolated from diarrheal patients in Dhaka 
(59). Overall, dissemination of ESBLs in Bangladesh seems to 
have reached all ecological niches, indicating that environmental 
contamination by antibiotic resistance is already quite high and 
probably widespread, from coastlines of the Bay of Bengal, to 
urban Dhaka, and to rural inland areas.
Emergence of blaNDM-1-mediated carbapenemase resistance 
was first described in Bangladesh in the Enterobacteriaceae in 2010 
(60). Subsequent retrospective studies demonstrated the presence 
of blaNDM-1 in clinical Klebsiella pneumoniae isolated in 2008 (61). 
The same investigators also reported a 9% prevalence of fecal car-
riage of plasmid-encoded blaNDM-1 in diverse Enterobacteriaceae 
in the patient population (62). The problematic spread of car-
bapenemase in Bangladesh has been documented with the isola-
tion of clinical A. baumannii, P. aeruginosa, and K. pneumoniae 
carrying genes encoding multiple enzymes, i.e., blaVIM-1, blaVIM-2, 
blaIMP-1, blaIMP-2, and/or blaNDM-1 (63). The same bacterial species 
have been detected in environmental water/sewage samples col-
lected in Dhaka (64), documenting a high level of environmental 
distribution of blaNDM-1, a worrisome finding given the high levels 
of sewage-derived bacteria routinely isolated from drinking water 
in Bangladesh (65).
The role of plasmids in the successful spread of β-lactamase 
genes has been extensively described (66, 67) and their involve-
ment in antibiotic resistance epidemiology in Bangladesh is no 
different. Although limited data are available, conjugative plas-
mids of various sizes (20–100 MDa) have been reported to carry 
ESBL genes (53, 61, 68), blaNDM-1, and/or other carbapenemases 
(60, 63), mostly in the metropolitan area of Dhaka.
ANtiMicrOBiAL resistANce 
sUrveiLLANce iN V. cholerae  
iN BANGLADesH
To date, ESBL or carbapenemase-producing V. cholerae in 
Bangladesh have not been reported. V. cholerae, E. coli, as well 
as other Enterobacteriaceae, can coexist in different ecological 
niches. Given the ability of conjugative plasmids to transfer natu-
rally between enterobacterial populations in the intestinal gut 
(68), the aquatic environment is now an ideal setting for acquisi-
tion and dissemination of antibiotic resistance (69), and the 
horizontal transfer of ESBL/carbapenemase genes to V.  cholerae 
cannot be excluded.
tABLe 1 | susceptibility vs. resistance (%) in V. cholerae O1 isolates from Bangladesh.
Antibiotica Mathbaria (n = 298) chhatak (n = 162)
clinical (n = 178) environmental (n = 120) clinical (n = 141) environmental (n = 21)
s i r s i r s i r s i r
Ampicillin 63 35 2 73 26 1 80 20 0 90 10 0
Penicillin 16 67 17 23 63 14 35 52 13 19 76 5
Cefoxitin 62 36 2 77 22 1 77 23 0 81 19 0
Cefotaxime 82 17 1 87 12 1 95 3 2 100 0 0
Ceftazidime 93 7 0 92 8 0 96 4 0 100 0 0
Ceftriaxone 75 24 1 84 16 0 84 16 0 95 5 0
Aztreonam 84 15 1 89 10 1 88 12 0 95 5 0
S, susceptible; I, intermediate; R, resistant.
aAll isolates were susceptible to cefepime and imipenem.
FiGUre 1 | Antibiotic sensitivity pattern of V. cholerae O1 during epidemiological surveillance (2009–2014). Number of isolates varied per year depending 
on results of sampling: 2009 (n = 4), 2010 (n = 66), 2011 (n = 86), 2012 (n = 76), 2013 (n = 176), and 2014 (n = 50). AM, ampicillin; P, penicillin; FOX, cefoxitin; 
FOT, cefotaxime; TAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam. Concentrations are expressed as micrograms per disk. All isolates were susceptible to 
cefepime and imipenem. S, susceptible; I, intermediate; R, resistant.
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In this perspective, we investigated β-lactam resistance1 in 
V. cholerae O1 collected during ecological and epidemiological 
surveillance in Bangladesh, the sampling and isolation details of 
which are described elsewhere (70). A total of 460 V. cholerae O1 
isolates were collected between 2009 and 2014 in the provinces 
of Mathbaria (MB; southwestern Bangladesh) and Chhatak 
(CH; northeastern Bangladesh) and analyzed. The set of strains 
included clinical (C) and environmental (E) isolates (MB: C = 178 
and E = 120; CH: C = 141 and E = 21), either from fecal samples 
of cholera patients at local health-care facilities or from ponds 
used for drinking water and other domestic purposes.
Resistance to penicillin (ampicillin and penicillin), mono-
bactams (aztreonam), carbapenems (imipenem), second- 
(cefoxitin), third- (cefotaxime, ceftazidime, and ceftriaxone), 
and fourth- (cefepime) generation cephalosporins was tested by 
disk diffusion, and the results were interpreted according to CLSI 
clinical breakpoints, for V. cholerae (71) or Enterobacteriaceae 
(72). All 460 V. cholerae isolates were found to be susceptible 
to imipenem and to fourth-generation cephalosporin cefepime. 
Seventy-two isolates showed resistance to one or more third-
generation cephalosporins (cefoxitin, cefotaxime, and ceftazi-
dime) ampicillin, and aztreonam (Table 1). Of those isolates, 57 
were resistant only to penicillin. Intrinsic resistance to penicillin 
has been observed in several V. cholerae strains, including 
V.  cholerae N16961 (73), and it is likely to be mediated by peni-
cillin insensitive transglycolase domains in penicillin binding 
proteins PBP1A and PBP1B. The majority of isolates were also 
resistant to carbenicillin (data not shown), very likely correlated 
1 Routine antibiotic resistance screening was also performed, results of which are 
beyond the scope of this article and will be reported elsewhere. 
with intrinsic resistance to penicillin, as described previously in 
V. parahaemolyticus (74). The second most common resistance 
was to third-generation cephalosporin, cefotaxime alone, or in 
combination with penicillin, ceftriaxone, or aztreonam. The latter 
was found only in Mathbaria. Overall, no remarkable difference 
was observed between the two geographical locations (Table 1) 
or during the 5 years of the study (Figure 1). As expected, the 
majority of resistant isolates were of clinical origin, compared to 
environmental sources (Table 1), and the most extensive resist-
ance profile was observed in a clinical strain isolated in 2013 from 
Mathbaria (Am, Pen, Fox, and Cro). Interestingly, several clinical 
isolates showed an intermediate phenotype, indicating evolution 
toward a resistant phenotype in the clinical environment, where 
the selective pressure of antibiotic use/misuse is higher than in 
the aquatic environment, where antibiotics may be less prevalent 
or at lower concentration.
Isolates showing reduced susceptibility were screened to 
detect the ESBL (blaCTX, blaTEM, and blaSHV), AmpC (blaMOX, blaCIT, 
blaDHA, blaACC, blaEBC, and blaFOX), and carbapenemase genes 
(blaIMP, blaSPM, blaVIM, blaBIC, blaNDM, blaKPC, blaAIM, blaSIM, blaDIM, 
and blaGIM), as previously reported (75–79). The results were 
negative for all isolates. The combination disk test results with 
clavulanic acid to detect ESBL for cefotaxime and ceftazidime-
resistant isolates (72) and the phenotypic AmpC disk test with 
Tris–EDTA (80) were also negative, confirming the absence of 
an ESBL/AmpC phenotype. To date, the enzyme(s) responsible 
for the reduced susceptibility phenotype have not been identified. 
The presence of alternative resistance mechanisms or an intrinsic 
resistance cannot be ruled out, as observed earlier for V. cholerae 
non-O1/non-O139 in Germany (81) and for V. parahaemolyticus 
isolates from shellfish in Italy (82).
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cONcLUDiNG reMArKs
Vibrio cholerae remains quite susceptible to β-lactams, despite the 
fact that other enteric pathogens, mostly Enterobacteriaceae, have 
developed this resistance in the same geographic regions (52, 59, 
63). Yet, a trend showing an increase in intermediate-susceptible 
isolates was observed, especially in clinical settings, highlighting 
a developmental path to a resistance phenotype.
The contribution of conjugative plasmids, or other mobile 
elements, in the horizontal acquisition of genetic factors con-
ferring β-lactam resistance must not be underestimated. It has 
been established that V. cholerae, independent of serotype, has 
a plastic genome and a long history of successful association 
with plasmids that have helped to shape the multi-resistant 
phenotype that now characterizes this pathogen (18, 22, 
24). Plasmids encoding ESBLs have been shown to possess a 
wide bacterial host range (67) and the ICEs of the SXT/R391 
family play a major role in antibiotic resistance acquisition 
by the Vibrionaceae (83). ICEPmiJpn1, encoding blaCMY-2 and 
conferring resistance to third-generation cephalosporins 
(77), can successfully be transferred among clinically relevant 
Enterobacteriaceae and readily disseminated to V. cholerae, 
one of its natural bacterial hosts. V. cholerae may very well act 
as an environmental reservoir for antibiotic resistance genes, 
contributing to genetic plasticity and dissemination. Finally, 
the presence of β-lactamase-producing bacteria in the aquatic 
environment renders environmental surveillance mandatory in 
order to monitor the role of the natural environment in the 
distribution of antibiotic resistance and to track potentially 
clinically relevant V. cholerae isolates.
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